Metabolic therapy: A new paradigm for managing malignant brain cancer

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 289-300

  Seyfried, Thomas N ^a   Flores, Roberto ^a   Poff, Angela M ^b   D'Agostino, Dominic P ^b   Mukherjee, Purna ^a  

^a Biology Department   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Brain tumor; Caloric restriction; Energy metabolism; Glioma; Ketogenic diet

Indexed keywords

CYTOTOXIC AGENT; GLUCOSE; GLUTAMINE;

AEROBIC METABOLISM; AMINO ACID METABOLISM; BRAIN CANCER; CALORIC RESTRICTION; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CYTOMEGALOVIRUS INFECTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; FERMENTATION; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; INFLAMMATION; KETOGENIC DIET; MACROPHAGE; METABOLIC THERAPY; MICROGLIA; NONHUMAN; SHORT SURVEY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; WARBURG EFFECT; BRAIN NEOPLASMS; CYTOMEGALOVIRUS; DIET; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; VIROLOGY;

CYTOMEGALOVIRUS;

BRAIN NEOPLASMS; CYTOMEGALOVIRUS; DIET; ENERGY METABOLISM; GLIOBLASTOMA; GLUCOSE; GLUTAMINE; GLYCOLYSIS; HUMANS; KETOGENIC DIET; MACROPHAGES; MICROGLIA; MITOCHONDRIA; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84920113647     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.015     Document Type: Review

References (258)

1. Fisher P.G., Buffler P.A. Malignant gliomas in 2005: where to GO from here?. JAMA 2005, 293(2005):615-617.
2. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
3. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., Weller M., Schackert G. Long-term survival with glioblastoma multiforme. Brain 2007, 130:2596-2606.
4. Karsy M., Gelbman M., Shah P., Balumbu O., Moy F., Arslan E. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol. 2012, 50:301-321.
5. Chen R., Nishimura M.C., Bumbaca S.M., Kharbanda S., Forrest W.F., Kasman I.M., Greve J.M., Soriano R.H., Gilmour L.L., Rivers C.S., Modrusan Z., Nacu S., Guerrero S., Edgar K.A., Wallin J.J., Lamszus K., Westphal M., Heim S., James C.D., VandenBerg S.R., Costello J.F., Moorefield S., Cowdrey C.J., Prados M., Phillips H.S. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010, 17:362-375.
6. Ohgaki H., Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009, 100:2235-2241.
7. Prestegarden L., Svendsen A., Wang J., Sleire L., Skaftnesmo K.O., Bjerkvig R., Yan T., Askland L., Persson A., Sakariassen P.O., Enger P.O. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res. 2010, 70:4274-4279.
8. Tso C.L., Shintaku P., Chen J., Liu Q., Liu J., Chen Z., Yoshimoto K., Mischel P.S., Cloughesy T.F., Liau L.M., Nelson S.F. Primary glioblastomas express mesenchymal stem-like properties. Mol. Cancer Res. 2006, 4:607-619.
9. Rubinstein L.J. Tumors of the central nervous system 1972, Armed Forces Institute of Pathology, Washington, DC.
10. Lopes M.B.S., Vanbenberg S.R., Scheithauer B.W. The world health organization classification of nervous system tumors in experimental neuro-oncology. Molecular Genetics of Nervous System Tumors 1993, 1-36. John Wiley & Sons, New York. A.J.L.H.H. Schmidek (Ed.).
11. Johnson B.E., Mazor T., Hong C., Barnes M., Aihara K., McLean C.Y., Fouse S.D., Yamamoto S., Ueda H., Tatsuno K., Asthana S., Jalbert L.E., Nelson S.J., Bollen A.W., Gustafson W.C., Charron E., Weiss W.A., Smirnov I.V., Song J.S., Olshen A.B., Cha S., Zhao Y., Moore R.A., Mungall A.J., Jones S.J., Hirst M., Marra M.A., Saito N., Aburatani H., Mukasa A., Berger M.S., Chang S.M., Taylor B.S., Costello J.F. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014, 343:189-193. (New York, NY).
12. Sanai N., Chang S., Berger M.S. Low-grade gliomas in adults. J. Neurosurg. 2011, 115:948-965.
13. Shinonaga M., Chang C.C., Suzuki N., Sato M., Kuwabara T. Immunohistological evaluation of macrophage infiltrates in brain tumors. Correlation with peritumoral edema. J. Neurosurg. 1988, 68:259-265.
14. Nishie A., Ono M., Shono T., Fukushi J., Otsubo M., Onoue H., Ito Y., Inamura T., Ikezaki K., Fukui M., Iwaki T., Kuwano M. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res. 1999, 5:1107-1113.
15. Phillips J.P., Eremin O., Anderson J.R. Lymphoreticular cells in human brain tumours and in normal brain. Br. J. Cancer 1982, 45:61-69.
16. Seyfried T.N., Shelton L.M., Mukherjee P. Does the existing standard of care increase glioblastoma energy metabolism?. Lancet Oncol. 2010, 11:811-813.
17. Morantz R.A., Wood G.W., Foster M., Clark M., Gollahon K. Macrophages in experimental and human brain tumors. Part 2: Studies of the macrophage content of human brain tumors. J. Neurosurg. 1979, 50:305-311.
18. Seyfried T.N. Perspectives on brain tumor formation involving macrophages, glia, and neural stem cells. Perspect. Biol. Med. 2001, 44:263-282.
19. Lewis C., Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Pathol. 2005, 167:627-635.
20. Pawelek J.M., Chakraborty A.K. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat. Rev. 2008, 8:377-386.
21. Powell A.E., Anderson E.C., Davies P.S., Silk A.D., Pelz C., Impey S., Wong M.H. Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res. 2011, 71:1497-1505.
22. Persson A., Englund E. Phagocytic properties in tumor astrocytes. Neuropathology 2012, 32:252-260.
23. Schramm H.M. Should EMT of cancer cells be understood as epithelial-myeloid transition?. J. Cancer 2014, 5:125-132.
24. Huysentruyt L.C., Akgoc Z., Seyfried T.N. Hypothesis: are neoplastic macrophages/microglia present in glioblastoma multiforme?. ASN Neuro 2011, 3.
25. Seyfried T.N., Huysentruyt L.C. On the origin of cancer metastasis. Crit. Rev. Oncog. 2013, 18:43-73.
26. Liwnicz B.H., Rubinstein L.J. The pathways of extraneural spread in metastasizing gliomas: a report of three cases and critical review of the literature. Hum. Pathol. 1979, 10:453-467.
27. Kalokhe G., Grimm S.A., Chandler J.P., Helenowski I., Rademaker A., Raizer J.J. Metastatic glioblastoma: case presentations and a review of the literature. J. Neurooncol. 2012, 107:21-27.
28. Beauchesne P. Extra-neural metastases of malignant gliomas: myth or reality?. Cancers (Basel) 2011, 3:461-477.
29. Armanios M.Y., Grossman S.A., Yang S.C., White B., Perry A., Burger P.C., Orens J.B. Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature. Neuro-oncology 2004, 6:259-263.
30. Lun M., Lok E., Gautam S., Wu E., Wong E.T. The natural history of extracranial metastasis from glioblastoma multiforme. J. Neuro-oncol. 2011, 105:261-273.
31. Talacchi A., Turazzi S., Locatelli F., Sala F., Beltramello A., Alessandrini F., Manganotti P., Lanteri P., Gambin R., Ganau M., Tramontano V., Santini B., Gerosa M. Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: a 171-patient series. J. Neuro-oncol. 2010, 100:417-426.
32. Kallenberg K., Bock H.C., Helms G., Jung K., Wrede A., Buhk J.H., Giese A., Frahm J., Strik H., Dechent P., Knauth M. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 2009, 253:805-812.
33. Zagzag D., Esencay M., Mendez O., Yee H., Smirnova I., Huang Y., Chiriboga L., Lukyanov E., Liu M., Newcomb E.W. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am. J. Pathol. 2008, 173:545-560.
34. Scherer H.J. Structural development in gliomas. Am. J. Cancer 1938, 34.
35. Nickel G.C., Barnholtz-Sloan J., Gould M.P., McMahon S., Cohen A., Adams M.D., Guda K., Cohen M., Sloan A.E., LaFramboise T. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS One 2012, 7:e35262.
36. Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushmehr H., Salama S.R., Zheng S., Chakravarty D., Sanborn J.Z., Berman S.H., Beroukhim R., Bernard B., Wu C.J., Genovese G., Shmulevich I., Barnholtz-Sloan J., Zou L., Vegesna R., Shukla S.A., Ciriello G., Yung W.K., Zhang W., Sougnez C., Mikkelsen T., Aldape K., Bigner D.D., Van Meir E.G., Prados M., Sloan A., Black K.L., Eschbacher J., Finocchiaro G., Friedman W., Andrews D.W., Guha A., Iacocca M., O'Neill B.P., Foltz G., Myers J., Weisenberger D.J., Penny R., Kucherlapati R., Perou C.M., Hayes D.N., Gibbs R., Marra M., Mills G.B., Lander E., Spellman P., Wilson R., Sander C., Weinstein J., Meyerson M., Gabriel S., Laird P.W., Haussler D., Getz G., Chin L. The somatic genomic landscape of glioblastoma. Cell 2013, 155:462-477.
37. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812. (New York, NY).
38. Salk J.J., Fox E.J., Loeb L.A. Mutational heterogeneity in human cancers: origin and consequences. Annu. Rev. Pathol. 2010, 5:51-75.
39. Poff A.M., Ari C., Arnold P., Seyfried T.N., D'Agostino D.P. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int J. Cancer. J Int. Cancer 2014, 135:1711-1720.
40. Seyfried T.N. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, John Wiley & Sons, Hoboken.
41. Samper E., Nicholls D.G., Melov S. Mitochondrial oxidative stress causes chromosomal instability of mouse embryonic fibroblasts. Aging Cell 2003, 2:277-285.
42. Lu J., Sharma L.K., Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009, 19:802-815.
43. Guha M., Avadhani N.G. Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. Mitochondrion 2013, 13:577-591.
44. Jazwinski S.M. The retrograde response links metabolism with stress responses, chromatin-dependent gene activation, and genome stability in yeast aging. Gene 2005, 354:22-27.
45. Nargund A.M., Pellegrino M.W., Fiorese C.J., Baker B.M., Haynes C.M. Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation. Science 2012, 337:587-590. (New York, NY).
46. Al Mamun A.A., Lombardo M.J., Shee C., Lisewski A.M., Gonzalez C., Lin D., Nehring R.B., Saint-Ruf C., Gibson J.L., Frisch R.L., Lichtarge O., Hastings P.J., Rosenberg S.M. Identity and function of a large gene network underlying mutagenic repair of DNA breaks. Science 2012, 338:1344-1348. (New York, NY).
47. Erol A. Retrograde regulation due to mitochondrial dysfunction may be an important mechanism for carcinogenesis. Med. Hypotheses 2005, 65:525-529.
48. Singh K.K., Kulawiec M., Still I., Desouki M.M., Geradts J., Matsui S. Inter-genomic cross talk between mitochondria and the nucleus plays an important role in tumorigenesis. Gene 2005, 354:140-146.
49. Lv S., Teugels E., Sadones J., Quartier E., Huylebrouck M., Du Four Stephanie, Le Mercier Marie, De Witte Olivier, Salmon I., Michotte A., De Grève Jacques, Neyns B. Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res. 2011, 31:4457-4463.
50. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., Ding J., Lei Q., Guan K.L., Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265. (New York, NY).
51. Marsh J., Mukherjee P., Seyfried T.N. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin. Cancer Res. 2008, 14:7751-7762.
52. Garber K. Oncometabolite? IDH1 discoveries raise possibility of new metabolism targets in brain cancers and leukemia. J. Natl Cancer Inst. 2010, 102:926-928.
53. Soto A.M., Sonnenschein C. The somatic mutation theory of cancer: growing problems with the paradigm?. BioEssays 2004, 26:1097-1107.
54. Menendez J.A., Joven J., Cufi S., Corominas-Faja B., Oliveras-Ferraros C., Cuyas E., Martin-Castillo B., Lopez-Bonet E., Alarcon T., Vazquez-Martin A. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell cycle 2013, 12:1166-1179. (Georgetown, Tex).
55. Stupp R., Tonn J.C., Brada M., Pentheroudakis G. High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21(Suppl 5):v190-193.
56. Mrugala M.M. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov. Med. 2013, 15:221-230.
57. Mason W.P., Maestro R.D., Eisenstat D., Forsyth P., Fulton D., Laperriere N., Macdonald D., Perry J., Thiessen B. Canadian recommendations for the treatment of glioblastoma multiforme. Curr. Oncol. 2007, 14:110-117.
58. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
59. Niewald M., Berdel C., Fleckenstein J., Licht N., Ketter R., Rube C. Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluation. Radiat. Oncol. 2011, 6:141.
60. Yin A.A., Zhang L.H., Cheng J.X., Dong Y., Liu B.L., Han N., Zhang X. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. PLoS One 2013, 8:e74242.
61. M. Markstein, S. Dettorre, J. Cho, R.A. Neumuller, S. Craig-Muller, N. Perrimon, Systematic screen of chemotherapeutics in Drosophila stem cell tumors, in: Proceedings of the National Academy of Sciences of the United States of America, 2014.
62. Koehler P.J. Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995, 6:19-33.
63. Chang S.M., Parney I.F., Huang W., Anderson F.A., Asher A.L., Bernstein M., Lillehei K.O., Brem H., Berger M.S., Laws E.R. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005, 293:557-564.
64. Burton T.M., Dooren J.C. Key FDA Approval Yanked for Avastin 2011, Wall Street Journal, NY.
65. Seyfried T.N., Marsh J., Shelton L.M., Huysentruyt L.C., Mukherjee P. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer?. Epilepsy Res. 2012, 100:310-326.
66. Han K., Ren M., Wick W., Abrey L., Das A., Jin J., Reardon D.A. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro-oncology 2014, 16:696-706.
67. Souhami L., Seiferheld W., Brachman D., Podgorsak E.B., Werner-Wasik M., Lustig R., Schultz C.J., Sause W., Okunieff P., Buckner J., Zamorano L., Mehta M.P., Curran W.J. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60:853-860.
68. Davis F.G., Freels S., Grutsch J., Barlas S., Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J. Neurosurg. 1998, 88:1-10.
69. Feichtinger R.G., Weis S., Mayr J.A., Zimmermann F., Geilberger R., Sperl W., Kofler B. Alterations of oxidative phosphorylation complexes in astrocytomas. Glia 2014, 62:514-525.
70. Feichtinger R.G., Zimmermann F., Mayr J.A., Neureiter D., Hauser-Kronberger C., Schilling F.H., Jones N., Sperl W., Kofler B. Low aerobic mitochondrial energy metabolism in poorly- or undifferentiated neuroblastoma. BMC Cancer 2010, 10:149.
71. Pedersen P.L. Tumor mitochondria and the bioenergetics of cancer cells. Prog. Exp. Tumor Res. 1978, 22:190-274.
72. Katsetos C.D., Anni H., Draber P. Mitochondrial dysfunction in gliomas. Semin. Pediatr. Neurol. 2013, 20:216-227.
73. Ordys B.B., Launay S., Deighton R.F., McCulloch J., Whittle I.R. The role of mitochondria in glioma pathophysiology. Mol. Neurobiol. 2010, 42:64-75.
74. Seyfried T.N. Respiratory Dysfunction in Cancer Cells, in, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, John Wiley & Sons, Hoboken, NJ, pp. 73-105.
75. Meixensberger J., Herting B., Roggendorf W., Reichmann H. Metabolic patterns in malignant gliomas. J. Neurooncol. 1995, 24:153-161.
76. John A.P. Dysfunctional mitochondria, not oxygen insufficiency, cause cancer cells to produce inordinate amounts of lactic acid: the impact of this on the treatment of cancer. Med. Hypotheses 2001, 57:429-431.
77. Roskelley R.C., Mayer N., Horwitt B.N., Salter W.T. Studies in cancer. Vii. Enzyme deficiency in human and experimental cancer. J. Clin. Investig. 1943, 22:743-751.
78. Arismendi-Morillo G. Electron microscopy morphology of the mitochondrial network in human cancer. Int. J. Biochem. Cell Biol. 2009, 41:2062-2068.
79. Arismendi-Morillo G.J., Castellano-Ramirez A.V. Ultrastructural mitochondrial pathology in human astrocytic tumors: potentials implications pro-therapeutics strategies. J. Electron. Microsc. (Tokyo) 2008, 57:33-39.
80. Carew J.S., Huang P. Mitochondrial defects in cancer. Mol. Cancer 2002, 1:9.
81. Villalobo A., Lehninger A.L. The proton stoichiometry of electron transport in Ehrlich ascites tumor mitochondria. J. Biol. Chem. 1979, 254:4352-4358.
82. Ramanathan A., Wang C., Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl. Acad. Sci. USA 2005, 102:5992-5997.
83. Cuezva J.M., Krajewska M., de Heredia M.L., Krajewski S., Santamaria G., Kim H., Zapata J.M., Marusawa H., Chamorro M., Reed J.C. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 2002, 62:6674-6681.
84. Seyfried T.N., Shelton L.M. Cancer as a metabolic disease. Nutr. Metab. 2010, 7:7.
85. Kiss G., Konrad C., Pour-Ghaz I., Mansour J.J., Nemeth B., Starkov A.A., Adam-Vizi V., Chinopoulos C. Mitochondrial diaphorases as NAD(+) donors to segments of the citric acid cycle that support substrate-level phosphorylation yielding ATP during respiratory inhibition. Faseb. J. 2014, 28:1682-1697.
86. Bayley J.P., Devilee P. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?. Curr. Opin. Genet. Dev. 2010, 20:324-329.
87. Kiebish M.A., Seyfried T.N. Absence of pathogenic mitochondrial DNA mutations in mouse brain tumors. BMC Cancer 2005, 5:102.
88. Yeung K.Y., Dickinson A., Donoghue J.F., Polekhina G., White S.J., Grammatopoulos D.K., McKenzie M., Johns T.G., John J.C. The identification of mitochondrial DNA variants in glioblastoma multiforme. Acta Neuropathol. Commun. 2014, 2:1.
89. Sipe J.C., Herman M.M., Rubinstein L.J. Electron microscopic observations on human glioblastomas and astrocytomas maintained in organ culture systems. Am. J. Pathol. 1973, 73:589-606.
90. Scheithauer B.W., Bruner J.M. The ultrastructural spectrum of astrocytic neoplasms. Ultrastruct. Pathol. 1987, 11:535-581.
91. Deighton R.F., Le Bihan T., Martin S.F., Gerth A.M., McCulloch M., Edgar J.M., Kerr L.E., Whittle I.R., McCulloch J. Interactions among mitochondrial proteins altered in glioblastoma. J. Neurooncol. 2014, 118:247-256.
92. Arismendi-Morillo G. Electron microscopy morphology of the mitochondrial network in gliomas and their vascular microenvironment. Biochim. Biophys. Acta 1807, 2011:602-608.
93. Galluzzi L., Morselli E., Kepp O., Vitale I., Rigoni A., Vacchelli E., Michaud M., Zischka H., Castedo M., Kroemer G. Mitochondrial gateways to cancer. Mol. Aspects Med. 2010, 31:1-20.
94. Kiebish M.A., Han X., Cheng H., Seyfried T.N. In vitro growth environment produces lipidomic and electron transport chain abnormalities in mitochondria from non-tumorigenic astrocytes and brain tumours. ASN Neuro 2009, 1:e00011.
95. Kiebish M.A., Han X., Cheng H., Chuang J.H., Seyfried T.N. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J. Lipid Res. 2008, 49:2545-2556.
96. Seyfried T.N., El-Abbadi M., Roy M.L. Ganglioside distribution in murine neural tumors. Mol. Chem. Neuropathol. 1992, 17:147-167.
97. Huysentruyt L.C., Mukherjee P., Banerjee D., Shelton L.M., Seyfried T.N. Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model. Int. J. Cancer 2008, 123:73-84.
98. Chicco A.J., Sparagna G.C. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am. J. Physiol. Cell Physiol. 2007, 292:C33-44.
99. Fry M., Green D.E. Cardiolipin requirement for electron transfer in complexs I and III of the mitochondrial respiratory chain. J. Biol. Chem. 1981, 256:1874-1880.
100. Claypool S.M., Koehler C.M. The complexity of cardiolipin in health and disease. Trends Biochem. Sci. 2012, 37:32-41.
101. Oudard S., Boitier E., Miccoli L., Rousset S., Dutrillaux B., Poupon M.F. Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res. 1997, 17:1903-1911.
102. Marin-Valencia I., Yang C., Mashimo T., Cho S., Baek H., Yang X.L., Rajagopalan K.N., Maddie M., Vemireddy V., Zhao Z., Cai L., Good L., Tu B.P., Hatanpaa K.J., Mickey B.E., Mates J.M., Pascual J.M., Maher E.A., Malloy C.R., Deberardinis R.J., Bachoo R.M. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012, 15:827-837.
103. Deighton R.F., Le Bihan T., Martin S.F., Barrios-Llerena M.E., Gerth A.M., Kerr L.E., McCulloch J., Whittle I.R. The proteomic response in glioblastoma in young patients. J. Neuro-oncol. 2014.
104. Oudard S., Arvelo F., Miccoli L., Apiou F., Dutrillaux A.M., Poisson M., Dutrillaux B., Poupon M.F. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br. J. Cancer 1996, 74:839-845.
105. Oudard S., Poirson F., Miccoli L., Bourgeois Y., Vassault A., Poisson M., Magdelenat H., Dutrillaux B., Poupon M.F. Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int. J. Cancer 1995, 62:216-222.
106. Renner C., Asperger A., Seyffarth A., Meixensberger J., Gebhardt R., Gaunitz F. Carnosine inhibits ATP production in cells from malignant glioma. Neurol. Res. 2010, 32:101-105.
107. Seyfried T.N., Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr. Metab. 2005, 2:30.
108. O. Warburg, The Metabolism of Tumours, Richard R. Smith, New York, 1931.
109. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314. (New York, NY).
110. Zu X.L., Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 2004, 313:459-465.
111. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. 2011, 11:325-337.
112. Cuezva J.M., Chen G., Alonso A.M., Isidoro A., Misek D.E., Hanash S.M., Beer D.G. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 2004, 25:1157-1163.
113. Ferreira L.M. Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol. 2010, 89:372-380.
114. Seyfried T.N. The Warburg Dispute, in, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, John Wiley & Sons, Hoboken, NJ, pp. 107-117.
115. Pedersen P.L. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. J. Bioenerg. Biomembr. 2007, 39:211-222.
116. Warburg O. On the respiratory impairment in cancer cells. Science 1956, 124:269-270. (New York, NY).
117. O. Warburg, Revised Lindau Lectures: The prime cause of cancer and prevention - Parts 1 & 2, in: D. Burk, (Ed.), Meeting of the Nobel-Laureates K. Triltsch, Lindau, Lake Constance, Germany, 1969, http://www.hopeforcancer.com/OxyPlus.htm.
118. Lichtor T., Dohrmann G.J. Respiratory patterns in human brain tumors. Neurosurgery 1986, 19:896-899.
119. Seyfried T.N. Mitochondria: The Ultimate Tumor Suppressor, in, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, John Wiley & Sons, Hoboken, NJ, pp. 195-205.
120. Carlson D.L., Sauerbier W., Rollins-Smith L.A., McKinnell R.G. Fate of herpesvirus DNA in embryos and tadpoles cloned from Lucke renal carcinoma nuclei. J. Comp. Pathol. 1994, 111:197-204.
121. McKinnell R.G., Deggins B.A., Labat D.D. Transplantation of pluripotential nuclei from triploid frog tumors. Science 1969, 165:394-396. (New York, NY).
122. Illmensee K., Mintz B. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc. Natl. Acad. Sci. USA 1976, 73:549-553.
123. Mintz B., Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. USA 1975, 72:3585-3589.
124. Li L., Connelly M.C., Wetmore C., Curran T., Morgan J.I. Mouse embryos cloned from brain tumors. Cancer Res. 2003, 63:2733-2736.
125. Hochedlinger K., Blelloch R., Brennan C., Yamada Y., Kim M., Chin L., Jaenisch R. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 2004, 18:1875-1885.
126. Israel B.A., Schaeffer W.I. Cytoplasmic suppression of malignancy. Vitro Cell Dev. Biol. 1987, 23:627-632.
127. Israel B.A., Schaeffer W.I. Cytoplasmic mediation of malignancy. Vitro Cell Dev. Biol. 1988, 24:487-490.
128. Howell A.N., Sager R. Tumorigenicity and its suppression in cybrids of mouse and Chinese hamster cell lines. Proc. Natl. Acad. Sci. USA 1978, 75:2358-2362.
129. Darlington C.D. The plasmagene theory of the origin of cancer. Br. J. Cancer 1948, 2:118-126.
130. Seyfried T.N., Flores R.E., Poff A.M., D'Agostino D.P. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 2014, 35:515-527.
131. L.M. Shelton, C.L. Strelko, M.F. Roberts, N.T. Seyfried, Krebs cycle substrate-level phosphorylation drives metastatic cancer cells, in: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, 2010.
132. Seyfried T.N. Is mitochondrial glutamine fermentation a missing link in the metabolic theory of cancer?. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, 133-144. John Wiley & Sons, Hoboken, NJ.
133. Chinopoulos C., Gerencser A.A., Mandi M., Mathe K., Torocsik B., Doczi J., Turiak L., Kiss G., Konrad C., Vajda S., Vereczki V., Oh R.J., Adam-Vizi V. Forward operation of adenine nucleotide translocase during F0F1-ATPase reversal: critical role of matrix substrate-level phosphorylation. FASEB J. 2010, 24:2405-2416.
134. Phillips D., Aponte A.M., French S.A., Chess D.J., Balaban R.S. Succinyl-CoA synthetase is a phosphate target for the activation of mitochondrial metabolism. Biochemistry 2009, 48:7140-7149.
135. Schwimmer C., Lefebvre-Legendre L., Rak M., Devin A., Slonimski P.P., di Rago J.P., Rigoulet M. Increasing mitochondrial substrate-level phosphorylation can rescue respiratory growth of an ATP synthase-deficient yeast. J. Biol. Chem. 2005, 280:30751-30759.
136. Pisarenko O.I., Solomatina E.S., Ivanov V.E., Studneva I.M., Kapelko V.I., Smirnov V.N. On the mechanism of enhanced ATP formation in hypoxic myocardium caused by glutamic acid. Basic Res. Cardiol. 1985, 80:126-134.
137. Weinberg J.M., Venkatachalam M.A., Roeser N.F., Nissim I. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc. Natl. Acad. Sci. USA 2000, 97:2826-2831.
138. Hochachka P.W., Owen T.G., Allen J.F., Whittow G.C. Multiple end products of anaerobiosis in diving vertebrates. Comp. Biochem. Physiol. B 1975, 50:17-22.
139. Hochachka P.W., Somero G.N. Biochemical Adaptation: Mechanism and Process in Physiological Evolution 2002, Oxford Press, New York.
140. King A., Selak M.A., Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006, 25:4675-4682.
141. Semenza G.L. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J. Bioenerg. Biomembr. 2007, 39:231-234.
142. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., Dang C.V., Semenza G.L. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11:407-420.
143. Yang D., Wang M.T., Tang Y., Chen Y., Jiang H., Jones T.T., Rao K., Brewer G.J., Singh K.K., Nie D. Impairment of mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L). Cancer Biol. Ther. 2010, 9:122-133.
144. Smiraglia D.J., Kulawiec M., Bistulfi G.L., Gupta S.G., Singh K.K. A novel role for mitochondria in regulating epigenetic modification in the nucleus. Cancer Biol. Ther. 2008, 7:1182-1190.
145. Delsite R.L., Rasmussen L.J., Rasmussen A.K., Kalen A., Goswami P.C., Singh K.K. Mitochondrial impairment is accompanied by impaired oxidative DNA repair in the nucleus. Mutagenesis 2003, 18:497-503.
146. Kulawiec M., Safina A., Desouki M.M., Still I., Matsui S.I., Bakin A., Singh K.K. Tumorigenic transformation of human breast epithelial cells induced by mitochondrial DNA depletion. Cancer Biol. Ther. 2008, 7.
147. Rasmussen A.K., Chatterjee A., Rasmussen L.J., Singh K.K. Mitochondria-mediated nuclear mutator phenotype in Saccharomyces cerevisiae. Nucleic Acids Res. 2003, 31:3909-3917.
148. Chandra D., Singh K.K. Genetic insights into OXPHOS defect and its role in cancer. Biochim. Biophys. Acta 2011, 1807:620-625.
149. Veatch J.R., McMurray M.A., Nelson Z.W., Gottschling D.E. Mitochondrial dysfunction leads to nuclear genome instability via an iron-sulfur cluster defect. Cell 2009, 137:1247-1258.
150. Seoane M., Mosquera-Miguel A., Gonzalez T., Fraga M., Salas A., Costoya J.A. The mitochondrial genome is a "Genetic Sanctuary" during the oncogenic process. PLoS One 2011, 6:e23327.
151. Minocherhomji S., Tollefsbol T.O., Singh K.K. Mitochondrial regulation of epigenetics and its role in human diseases. Epigenetics: Off. J. DNA Methylation Soc. 2012, 7:326-334.
152. T.N. Seyfried, Mitochondrial glutamine fermentation enhances ATP synthesis in murine glioblastoma cells, in: Proceedings of the 102nd Annual Meeting of the American Association Cancer Research, Orlando, FL, 2011.
153. Seyfried T.N., Sanderson T.M., El-Abbadi M.M., McGowan R., Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br. J. Cancer 2003, 89:1375-1382.
154. McKenna M.C., Gruetter R., Sonnewald U., Waagepetersen H.S., Schousboe A. Energy metabolism of the brain. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects 2006, 531-557. Elsevier Academic Press, New York. G.J. Siegel, R.W. Albers, S.T. Bradey, D.P. Price (Eds.).
155. Szerlip N., Rutter C., Ram N., Yovino S., Kwok Y., Maggio W., Regine W.F. Factors impacting volumetric white matter changes following whole brain radiation therapy. J. Neurooncol. 2011, 103:111-119.
156. Derr R.L., Ye X., Islas M.U., Desideri S., Saudek C.D., Grossman S.A. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2009, 27:1082-1086.
157. McGirt M.J., Chaichana K.L., Gathinji M., Attenello F., Than K., Ruiz A.J., Olivi A., Quinones-Hinojosa A. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 2008, 63:286-291. (discussion 291).
158. DeBerardinis R.J., Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29:313-324.
159. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., Zeller K.I., De Marzo A.M., Van Eyk J.E., Mendell J.T., Dang C.V. C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
160. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., Thompson C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 2008, 105:18782-18787.
161. Yuneva M. Finding an "Achilles' heel" of cancer: the role of glucose and glutamine metabolism in the survival of transformed cells. Cell cycle 2008, 7:2083-2089. (Georgetown, Tex).
162. Hawkins R.A. The blood-brain barrier and glutamate. Am. J. Clin. Nutr. 2009, 90:867S-874S.
163. Takano T., Lin J.H., Arcuino G., Gao Q., Yang J., Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat. Med. 2001, 7:1010-1015.
164. Nair S.K., De Leon G., Boczkowski D., Schmittling R., Xie W., Staats J., Liu R., Johnson L.A., Weinhold K., Archer G.E., Sampson J.H., Mitchell D.A. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2014, 20:2684-2694.
165. Rourke E.A., Lopez M.S., Monroy C.M., Scheurer M.E., Etzel C.J., Albrecht T., Bondy M.L., El-Zein R.A. Modulation of radiation-induced genetic damage by HCMV in peripheral blood lymphocytes from a brain tumor case-control study. Cancers (Basel) 2010, 2:420-435.
166. Hawkins C., Croul S. Viruses and human brain tumors: cytomegalovirus enters the fray. J. Clin. Investig. 2011, 121:3831-3833.
167. Michaelis M., Doerr H.W., Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 2009, 11:1-9.
168. Dziurzynski K., Chang S.M., Heimberger A.B., Kalejta R.F., McGregor Dallas S.R., Smit M., Soroceanu L., Cobbs C.S. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro-oncology 2012, 14:246-255.
169. Yu Y., Clippinger A.J., Alwine J.C. Viral effects on metabolism: changes in glucose and glutamine utilization during human cytomegalovirus infection. Trends Microbiol. 2011, 19:360-367.
170. Bozidis P., Williamson C.D., Wong D.S., Colberg-Poley A.M. Trafficking of UL37 proteins into mitochondrion-associated membranes during permissive human cytomegalovirus infection. J. Virol. 2010, 84:7898-7903.
171. Williamson C.D., Colberg-Poley A.M. Access of viral proteins to mitochondria via mitochondria-associated membranes. Rev. Med. Virol. 2009, 19:147-164.
172. Seyfried T.N. Genes, respiration, viruses, and cancer. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, 145-176. John Wiley & Sons, Hoboken, NJ.
173. Pawelek J.M., Chakraborty A.K. The cancer cell-leukocyte fusion theory of metastasis. Adv. Cancer Res. 2008, 101:397-444.
174. Dziurzynski K., Wei J., Qiao W., Hatiboglu M.A., Kong L.Y., Wu A., Wang Y., Cahill D., Levine N., Prabhu S., Rao G., Sawaya R., Heimberger A.B. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2011, 17:4642-4649.
175. Munzarova M., Rejthar A., Mechl Z. Do some malignant melanoma cells share antigens with the myeloid monocyte lineage?. Neoplasma 1991, 38:401-405.
176. Seyfried T.N., Marsh J., Mukherjee P., Zuccoli G., D'Agostino D.P. Could metabolic therapy become a viable alternative to the standard of care for managing glioblastoma?. US Neurol. 2014, 10:48-55.
177. Monje M.L., Vogel H., Masek M., Ligon K.L., Fisher P.G., Palmer T.D. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann. Neurol. 2007, 62:515-520.
178. Lee W.H., Sonntag W.E., Mitschelen M., Yan H., Lee Y.W. Irradiation induces regionally specific alterations in pro-inflammatory environments in rat brain. Int. J. Radiat. Biol. 2010, 86:132-144.
179. Di Chiro G., Oldfield E., Wright D.C., De Michele D., Katz D.A., Patronas N.J., Doppman J.L., Larson S.M., Ito M., Kufta C.V. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am. J. Roentgenol. 1988, 150:189-197.
180. Seyfried T.N. Cancer treatment strategies. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, 227-289. John Wiley & Sons, Hoboken, NJ.
181. Tannahill G.M., Curtis A.M., Adamik J., Palsson-McDermott E.M., McGettrick A.F., Goel G., Frezza C., Bernard N.J., Kelly B., Foley N.H., Zheng L., Gardet A., Tong Z., Jany S.S., Corr S.C., Haneklaus M., Caffrey B.E., Pierce K., Walmsley S., Beasley F.C., Cummins E., Nizet V., Whyte M., Taylor C.T., Lin H., Masters S.L., Gottlieb E., Kelly V.P., Clish C., Auron P.E., Xavier R.J., O'Neill L.A. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013, 496:238-242.
182. Xu R.H., Pelicano H., Zhou Y., Carew J.S., Feng L., Bhalla K.N., Keating M.J., Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005, 65:613-621.
183. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64:3892-3899.
184. Kargiotis O., Geka A., Rao J.S., Kyritsis A.P. Effects of irradiation on tumor cell survival, invasion and angiogenesis. J. Neurooncol. 2010, 100:323-338.
185. Zhuang W., Qin Z., Liang Z. The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim. Biophys. Sin. (Shanghai) 2009, 41:341-351.
186. Noch E., Khalili K. Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol. Ther. 2009, 8:1791-1797.
187. Lukins M.B., Manninen P.H. Hyperglycemia in patients administered dexamethasone for craniotomy. Anesth. Analg. 2005, 100:1129-1133.
188. Hans P., Vanthuyne A., Dewandre P.Y., Brichant J.F., Bonhomme V. Blood glucose concentration profile after 10 mg dexamethasone in non-diabetic and type 2 diabetic patients undergoing abdominal surgery. Br. J. Anaesth. 2006, 97:164-170.
189. Reardon D.A., Desjardins A., Peters K., Gururangan S., Sampson J., Rich J.N., McLendon R., Herndon J.E., Marcello J., Threatt S., Friedman A.H., Vredenburgh J.J., Friedman H.S. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J. Neurooncol. 2011, 103:371-379.
190. Iwamoto F.M., Abrey L.E., Beal K., Gutin P.H., Rosenblum M.K., Reuter V.E., DeAngelis L.M., Lassman A.B. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73:1200-1206.
191. de Groot J.F., Fuller G., Kumar A.J., Piao Y., Eterovic K., Ji Y., Conrad C.A. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology 2010, 12:233-242.
192. Jeyaretna D.S., Curry W.T., Batchelor T.T., Stemmer-Rachamimov A., Plotkin S.R. Exacerbation of cerebral radiation necrosis by bevacizumab. J. Clin. Oncol. 2011, 29:e159-162.
193. Stratton M.R. Exploring the genomes of cancer cells: progress and promise. Science 2011, 331:1553-1558. (New York, NY).
194. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
195. Schwartzentruber J., Korshunov A., Liu X.Y., Jones D.T., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D.A., Tonjes M., Hovestadt V., Albrecht S., Kool M., Nantel A., Konermann C., Lindroth A., Jager N., Rausch T., Ryzhova M., Korbel J.O., Hielscher T., Hauser P., Garami M., Klekner A., Bognar L., Ebinger M., Schuhmann M.U., Scheurlen W., Pekrun A., Fruhwald M.C., Roggendorf W., Kramm C., Durken M., Atkinson J., Lepage P., Montpetit A., Zakrzewska M., Zakrzewski K., Liberski P.P., Dong Z., Siegel P., Kulozik A.E., Zapatka M., Guha A., Malkin D., Felsberg J., Reifenberger G., von Deimling A., Ichimura K., Collins V.P., Witt H., Milde T., Witt O., Zhang C., Castelo-Branco P., Lichter P., Faury D., Tabori U., Plass C., Majewski J., Pfister S.M., Jabado N. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
196. Seyfried T.N. Metabolic management of cancer. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, 291-354. John Wiley & Sons, Hoboken, NJ.
197. Preusser M., de Ribaupierre S., Wohrer A., Erridge S.C., Hegi M., Weller M., Stupp R. Current concepts and management of glioblastoma. Ann. Neurol. 2011, 70:9-21.
198. T.N. Seyfried, P. Mukherjee, M. Kalamian, G. Zuccoli, The restricted ketogenic diet: an alternative treatment strategy for glioblastoma multiforme, in: R. Holcroft, (Ed.), Treatment Stratagies Oncology Cambridge Rse. Ctr., London, 2011, pp. 24-35, http://viewer.zmags.com.
199. VanItallie T.B., Nufert T.H. Ketones: metabolism's ugly duckling. Nutr. Rev. 2003, 61:327-341.
200. Drenick E.J., Alvarez L.C., Tamasi G.C., Brickman A.S. Resistance to symptomatic insulin reactions after fasting. J. Clin. Investig. 1972, 51:2757-2762.
201. Veech R.L. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot. Essent. Fatty Acids 2004, 70:309-319.
202. Krebs H.A., Williamson D.H., Bates M.W., Page M.A., Hawkins R.A. The role of ketone bodies in caloric homeostasis. Adv. Enzyme Reg. 1971, 9:387-409.
203. Cahill G.F. Starvation in man. N. Engl. J. Med. 1970, 282:668-675.
204. Cahill G.F. Fuel metabolism in starvation. Annu. Rev. Nutr. 2006, 26:1-22.
205. Cahill G.F., Veech R.L. Ketoacids? Good medicine?. Trans. Am. Clin. Climatol. Assoc. 2003, 114:149-161. (discussion 162-143).
206. Owen O.E., Morgan A.P., Kemp H.G., Sullivan J.M., Herrera M.G., Cahill G.F. Brain metabolism during fasting. J. Clin. Investig. 1967, 46:1589-1595.
207. Seyfried T.N. Cancer Prevention. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, 375-386. John Wiley & Sons, Hoboken, NJ.
208. Shimazu T., Hirschey M.D., Newman J., He W., Shirakawa K., Le Moan N., Grueter C.A., Lim H., Saunders L.R., Stevens R.D., Newgard C.B., Farese R.V., de Cabo R., Ulrich S., Akassoglou K., Verdin E. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013, 339:211-214. (New York, NY).
209. Skinner R., Trujillo A., Ma X., Beierle E.A. Ketone bodies inhibit the viability of human neuroblastoma cells. J. Pediatr. Surg. 2009, 44:212-216. (discussion 216).
210. Zhou W., Mukherjee P., Kiebish M.A., Markis W.T., Mantis J.G., Seyfried T.N. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr. Metab. 2007, 4:5.
211. Fredericks M., Ramsey R.B. 3-Oxo acid coenzyme a transferase activity in brain and tumors of the nervous system. J. Neurochem. 1978, 31:1529-1531.
212. Tisdale M.J. Role of acetoacetyl-CoA synthetase in acetoacetate utilization by tumor cells. Cancer Biochem. Biophys. 1984, 7:101-107.
213. Tisdale M.J., Brennan R.A. Loss of acetoacetate coenzyme a transferase activity in tumours of peripheral tissues. Br. J. Cancer 1983, 47:293-297.
214. Chang H.T., Olson L.K., Schwartz K.A. Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. Nutr. Metab. 2013, 10:47.
215. Seyfried T.N., Kiebish M.A., Marsh J., Shelton L.M., Huysentruyt L.C., Mukherjee P. Metabolic management of brain cancer. Biochim. Biophys. Acta 1807, 2011:577-594.
216. Maurer G.D., Brucker D.P., Baehr O., Harter P.N., Hattingen E., Walenta S., Mueller-Klieser W., Steinbach J.P., Rieger J. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer 2011, 11:315.
217. Magee B.A., Potezny N., Rofe A.M., Conyers R.A. The inhibition of malignant cell growth by ketone bodies. Aust. J. Exp. Biol. Med. Sci. 1979, 57:529-539.
218. Jiang Y.S., Wang F.R. Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J. Neurooncol. 2013, 114:25-32.
219. Mukherjee P., Abate L.E., Seyfried T.N. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin. Cancer Res. 2004, 10:5622-5629.
220. Mukherjee P., El-Abbadi M.M., Kasperzyk J.L., Ranes M.K., Seyfried T.N. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br. J. Cancer 2002, 86:1615-1621.
221. Mulrooney T.J., Marsh J., Urits I., Seyfried T.N., Mukherjee P. Influence of caloric restriction on constitutive expression of NF-kappaB in an experimental mouse astrocytoma. PLoS One 2011, 6:e18085.
222. Abdelwahab M.G., Fenton K.E., Preul M.C., Rho J.M., Lynch A., Stafford P., Scheck A.C. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One 2012, 7:e36197.
223. Seyfried T.N. Nothing in cancer biology makes sense except in the light of evolution. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer 2012, 261-275. John Wiley & Sons, Hoboken, NJ.
224. Simone B.A., Champ C.E., Rosenberg A.L., Berger A.C., Monti D.A., Dicker A.P., Simone N.L. Selectively starving cancer cells through dietary manipulation: methods and clinical implications. Future Oncol. 2013, 9:959-976.
225. Stafford P., Abdelwahab M.G., Kim do Y., Preul M.C., Rho J.M., Scheck A.C. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr. Metab. 2010, 7:74.
226. Fine E.J., Segal-Isaacson C.J., Feinman R.D., Herszkopf S., Romano M.C., Tomuta N., Bontempo A.F., Negassa A., Sparano J.A. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition 2012, 28:1028-1035.
227. Zuccoli G., Marcello N., Pisanello A., Servadei F., Vaccaro S., Mukherjee P., Seyfried T.N. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr. Metab. 2010, 7:33.
228. Nebeling L.C., Miraldi F., Shurin S.B., Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J. Am. Coll. Nutr. 1995, 14:202-208.
229. Champ C.E., Palmer J.D., Volek J.S., Werner-Wasik M., Andrews D.W., Evans J.J., Glass J., Kim L., Shi W. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J. Neuro-oncol. 2014, 117:125-131.
230. Shelton L.M., Huysentruyt L.C., Mukherjee P., Seyfried T.N. Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro 2010, 2:e00038.
231. Harik S.I., Al-Mudallal A.S., LaManna J.C., Lust W.D., Levin B.E. Ketogenic diet and the brain. Ann. N. Y. Acad. Sci. 1997, 835:218-224.
232. Ellenbroek J.H., van Dijck L., Tons H.A., Rabelink T.J., Carlotti F., Ballieux B.E., de Koning E.J. Long-term ketogenic diet causes glucose intolerance and reduced beta and alpha cell mass but no weight loss in mice. Am. J. Physiol. Endocrinol. Metab. 2014, 306:E552-E558.
233. Mahoney L.B., Denny C.A., Seyfried T.N. Caloric restriction in C57BL/6J mice mimics therapeutic fasting in humans. Lipids Health Dis. 2006, 5:13.
234. Morris A.A. Cerebral ketone body metabolism. J. Inherit. Metab. Dis. 2005, 28:109-121.
235. Veech R.L., Chance B., Kashiwaya Y., Lardy H.A., Cahill G.F. Ketone bodies, potential therapeutic uses. IUBMB Life 2001, 51:241-247.
236. Maalouf M., Rho J.M., Mattson M.P. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res. Rev. 2009, 59:293-315.
237. Newman J.C., Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol. Metab. 2014, 25:42-52.
238. Milder J., Patel M. Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res. 2012, 100:295-303.
239. Freeman J.M., Kossoff E.H. Ketosis and the ketogenic diet, 2010: advances in treating epilepsy and other disorders. Adv. Pediatr. 2010, 57(2010):315-329.
240. Woolf E.C., Scheck A.C. The ketogenic diet for the treatment of malignant glioma. J. Lipid Res. 2014, in press.
241. Kashiwaya Y., Pawlosky R., Markis W., King M.T., Bergman C., Srivastava S., Murray A., Clarke K., Veech R.L. A ketone ester diet increased brain malonyl CoA and uncoupling protein 4 and 5 while decreasing food intake in the normal Wistar rat. J. Biol. Chem. 2010, 285:25950-25956.
242. Yudkoff M., Daikhin Y., Melo T.M., Nissim I., Sonnewald U., Nissim I. The ketogenic diet and brain metabolism of amino acids: relationship to the anticonvulsant effect. Annu. Rev. Nutr. 2007, 27:415-430.
243. Michelakis E.D., Sutendra G., Dromparis P., Webster L., Haromy A., Niven E., Maguire C., Gammer T.L., Mackey J.R., Fulton D., Abdulkarim B., McMurtry M.S., Petruk K.C. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med. 2010, 2:31ra34.
244. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., Hullihen J., Pedersen P.L. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 2004, 324:269-275.
245. Marsh J., Mukherjee P., Seyfried T.N. Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-d-glucose and the restricted ketogenic diet. Nutr. Metab. 2008, 5:33.
246. Yu Y., Maguire T.G., Alwine J.C. Human cytomegalovirus activates glucose transporter 4 expression to increase glucose uptake during infection. J. Virol. 2011, 85:1573-1580.
247. Soderberg-Naucler C., Rahbar A., Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N. Engl. J. Med. 2013, 369:985-986.
248. Poff A.M., Ari C., Seyfried T.N., D'Agostino D.P. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One 2013, 8:e65522.
249. Chen Y., Cairns R., Papandreou I., Koong A., Denko N.C. Oxygen consumption can regulate the growth of tumors, a new perspective on the warburg effect. PLoS One 2009, 4:e7033.
250. Spitz D.R., Sim J.E., Ridnour L.A., Galoforo S.S., Lee Y.J. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?. Ann. N. Y. Acad. Sci. 2000, 899:349-362.
251. Kohshi K., Kinoshita Y., Imada H., Kunugita N., Abe H., Terashima H., Tokui N., Uemura S. Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas. Br. J. Cancer 1999, 80:236-241.
252. Harrison L., Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 2004, 9(Suppl 5):31-40.
253. Allen B.G., Bhatia S.K., Buatti J.M., Brandt K.E., Lindholm K.E., Button A.M., Szweda L.I., Smith B.J., Spitz D.R., Fath M.A. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2013, 19:3905-3913.
254. Denny C.A., Heinecke K.A., Kim Y.P., Baek R.C., Loh K.S., Butters T.D., Bronson R.T., Platt F.M., Seyfried T.N. Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice. J. Neurochem. 2010, 113:1525-1535.
255. Zafar S.Y., Currow D., Abernethy A.P. Defining best supportive care. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2008, 26:5139-5140.
256. Clarke K., Tchabanenko K., Pawlosky R., Carter E., Todd King M., Musa-Veloso K., Ho M., Roberts A., Robertson J., Vanitallie T.B., Veech R.L., Kinetics safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul. Toxicol. Pharmacol. 2012, 63:401-408.
257. D'Agostino D.P., Pilla R., Held H.E., Landon C.S., Puchowicz M., Brunengraber H., Ari C., Arnold P., Dean J.B. Therapeutic ketosis with ketone ester delays central nervous system oxygen toxicity seizures in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 304:R829-836.
258. Seyfried T.N., Kiebish M., Mukherjee P., Marsh J. Targeting energy metabolism in brain cancer with calorically restricted ketogenic diets. Epilepsia 2008, 49(Suppl 8):114-116.